Clinical Trials Browser

Phase 1/2 × Hodgkin Disease × ruxolitinib × Clear all

NCT03681561 2026-03-09

Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

Phase 1/2 Recruiting

Hodgkin Disease